(2) ITIH5681aa as well as the downsized ITIH5161aa fragment caused growth inhibition in a dose-dependent manner in these cancer cells, in which the suppressive impact of the full-length ITIH5 has been confirmed previously, i.e., in breast cancer [2,7], bladder cancer [3] and adenocarcinomas of the lung (NSCLC) [5]. This evidence concerns the gene ITIH5 and lung adenocarcinoma.